Clinical Trial Update: A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants [Phase 1]

View source ↗

Summary

Phase 1 study assessing absolute bioavailability and PK, metabolism, and excretion of TAK-831 in healthy volunteers completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Healthy Volunteers

Drugs mentioned

• TAK-831 (TAK-831)

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Healthy Volunteers | Phase 1 | Status: COMPLETED | Results posted: 2021-04-28